424 related articles for article (PubMed ID: 18195134)
21. An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients.
Martínez A; de las Heras V; Mas Fontao A; Bartolomé M; de la Concha EG; Urcelay E; Arroyo R
J Neuroimmunol; 2006 Apr; 173(1-2):196-9. PubMed ID: 16430971
[TBL] [Abstract][Full Text] [Related]
22. Implication of the Toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis.
Bustamante MF; Fissolo N; Río J; Espejo C; Costa C; Mansilla MJ; Lizasoain I; Moro MA; Carmen Edo M; Montalban X; Comabella M
Ann Neurol; 2011 Oct; 70(4):634-45. PubMed ID: 22028223
[TBL] [Abstract][Full Text] [Related]
23. A practical approach to immunomodulatory therapy for multiple sclerosis.
Burks JS
Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
[TBL] [Abstract][Full Text] [Related]
24. [Interferon -beta therapy in multiple sclerosis].
Satoh J
Nihon Rinsho; 2006 Jul; 64(7):1297-309. PubMed ID: 16838648
[TBL] [Abstract][Full Text] [Related]
25. Candidate gene analysis of SPARCL1 gene in patients with multiple sclerosis.
Scalabrini D; Fenoglio C; Scarpini E; De Riz M; Comi C; Venturelli E; Cortini F; Piola M; Villa C; Naldi P; Monaco F; Bresolin N; Galimberti D
Neurosci Lett; 2007 Oct; 425(3):173-6. PubMed ID: 17825989
[TBL] [Abstract][Full Text] [Related]
26. Gene expression analysis of interferon-beta treatment in multiple sclerosis.
Sellebjerg F; Datta P; Larsen J; Rieneck K; Alsing I; Oturai A; Svejgaard A; Soelberg Sørensen P; Ryder LP
Mult Scler; 2008 Jun; 14(5):615-21. PubMed ID: 18408020
[TBL] [Abstract][Full Text] [Related]
27. Clinical parameters to predict response to interferon in relapsing multiple sclerosis.
Fromont A; Debouverie M; Le Teuff G; Quantin C; Binquet C; Moreau T
Neuroepidemiology; 2008; 31(3):150-6. PubMed ID: 18716412
[TBL] [Abstract][Full Text] [Related]
28. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study.
Gauthier SA; Glanz BI; Mandel M; Tsagkaropoulos A; Neema M; Stankiewicz J; Arora A; Duan Y; Liptak Z; Egorova S; Buckle GJ; Bakshi R; Guttmann CR; Khoury SJ; Weiner HL
J Neurol Sci; 2009 Sep; 284(1-2):116-9. PubMed ID: 19428028
[TBL] [Abstract][Full Text] [Related]
29. NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis.
Malhotra S; Río J; Urcelay E; Nurtdinov R; Bustamante MF; Fernández O; Oliver B; Zettl U; Brassat D; Killestein J; Lechner-Scott J; Drulovic J; Chan A; Martinelli-Boneschi F; García-Merino A; Montalban X; Comabella M
Brain; 2015 Mar; 138(Pt 3):644-52. PubMed ID: 25586466
[TBL] [Abstract][Full Text] [Related]
30. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Birnbaum G; Cree B; Altafullah I; Zinser M; Reder AT
Neurology; 2008 Oct; 71(18):1390-5. PubMed ID: 18525027
[TBL] [Abstract][Full Text] [Related]
31. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
Malucchi S; Gilli F; Caldano M; Marnetto F; Valentino P; Granieri L; Sala A; Capobianco M; Bertolotto A
Neurology; 2008 Mar; 70(13 Pt 2):1119-27. PubMed ID: 18272865
[TBL] [Abstract][Full Text] [Related]
32. Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases.
Kieseier BC; Archelos JJ; Hartung HP
Arch Neurol; 2004 Jun; 61(6):929-32. PubMed ID: 15210533
[TBL] [Abstract][Full Text] [Related]
33. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.
Pakdaman H; Fallah A; Sahraian MA; Pakdaman R; Meysamie A
Neuropediatrics; 2006 Aug; 37(4):257-60. PubMed ID: 17177154
[TBL] [Abstract][Full Text] [Related]
34. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.
Comabella M; Río J; Espejo C; Ruiz de Villa M; Al-Zayat H; Nos C; Deisenhammer F; Baranzini SE; Nonell L; López C; Julià E; Oksenberg JR; Montalban X
Clin Immunol; 2009 Feb; 130(2):145-50. PubMed ID: 18945642
[TBL] [Abstract][Full Text] [Related]
35. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy.
Singh MK; Scott TF; LaFramboise WA; Hu FZ; Post JC; Ehrlich GD
J Neurol Sci; 2007 Jul; 258(1-2):52-9. PubMed ID: 17467740
[TBL] [Abstract][Full Text] [Related]
36. Association to the Glypican-5 gene in multiple sclerosis.
Lorentzen AR; Melum E; Ellinghaus E; Smestad C; Mero IL; Aarseth JH; Myhr KM; Celius EG; Lie BA; Karlsen TH; Franke A; Harbo HF
J Neuroimmunol; 2010 Sep; 226(1-2):194-7. PubMed ID: 20692050
[TBL] [Abstract][Full Text] [Related]
37. Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients.
Portaccio E; Zipoli V; Siracusa G; Sorbi S; Amato MP
Eur Neurol; 2009; 61(3):177-82. PubMed ID: 19129705
[TBL] [Abstract][Full Text] [Related]
38. Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?
Drulovic J; Savic E; Pekmezovic T; Mesaros S; Stojsavljevic N; Dujmovic-Basuroski I; Kostic J; Vasic V; Mostarica Stojkovic M; Popadic D
J Neuroimmunol; 2009 Oct; 215(1-2):90-5. PubMed ID: 19695714
[TBL] [Abstract][Full Text] [Related]
39. Zinc-ion binding and cytokine activity regulation pathways predicts outcome in relapsing-remitting multiple sclerosis.
Achiron A; Gurevich M; Snir Y; Segal E; Mandel M
Clin Exp Immunol; 2007 Aug; 149(2):235-42. PubMed ID: 17488294
[TBL] [Abstract][Full Text] [Related]
40. Multi-SNP pharmacogenomic classifier is superior to single-SNP models for predicting drug outcome in complex diseases.
Petrovski S; Szoeke CE; Sheffield LJ; D'souza W; Huggins RM; O'brien TJ
Pharmacogenet Genomics; 2009 Feb; 19(2):147-52. PubMed ID: 19077679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
